Richard Ferro, DO
Interventional Pain Medicine · Lansing, MINPI 1528008372
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 50.4% of the total. Reporting peaked in 2023 at $12,973 and has fallen 92.6% since, to $955 in 2025. Among interventional pain medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $97.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$16K
- Medtronic$11K
- Vertiflex, Inc.$1K
- Relievant Medsystems, Inc.$522
- Nevro Corp.$431
- Abbott$420
- plus $1K from 22 others
Across 47 payments — averaging $3741.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$176K
What the payments were for
- Consulting fees$4,00013%
- Speaking & faculty fees$16,55054%
- Travel & lodging$4,16314%
- Food & beverage$6,03920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 162 | $15,506 |
| Medtronic(2 entities) | 40 | $10,970 |
| Vertiflex, Inc. | 12 | $1,430 |
| Relievant Medsystems, Inc. | 8 | $522 |
| Nevro Corp. | 18 | $431 |
| Abbott | 11 | $420 |
| Stryker | 4 | $406 |
| Collegium Pharmaceutical, Inc. | 11 | $165 |
| Globus Medical | 5 | $159 |
| Pfizer | 8 | $123 |
| Si-bone, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| MDD US Operations, LLC | 4 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Amgen | 3 | $45 |
| Electronic Waveform Lab, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Spinal Simplicity, LLC | 1 | $29 |
| IBSA Pharma Inc. | 2 | $26 |
| Redhill Biopharma Inc. | 2 | $25 |
| GRT US Holding, Inc. | 2 | $24 |
| Baxter Healthcare | 1 | $22 |
| SPR Therapeutics, Inc | 1 | $22 |
| Novartis | 1 | $21 |
| AbbVie | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Vertex | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$10,014
- WAVEWRITER ALPHA$3,761
- SPECTRA WAVEWRITER$3,000
- GENERAL PAIN MANAGEMENT$2,311
- Intracept$1,462
- Superion ISS$1,224
- GENERAL - THERAPIES$800
- mild Device Kit$363
How this compares
$30,751 in reported general payments places this provider in the 90th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,147 | $26,186 |
| Xtampza ErOxycodone Myristate | 13 | $14,608 |
| MovantikNaloxegol Oxalate | 25 | $13,095 |
| OxycontinOxycodone Hcl | 12 | $6,895 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 144 | $4,806 |
| Morphine Sulfate | 36 | $1,496 |
| Oxycodone Hcl | 83 | $1,394 |
| Gabapentin | 94 | $1,337 |
| Pregabalin | 44 | $1,255 |
| Tramadol Hcl | 112 | $1,113 |
| Morphine Sulfate ErMorphine Sulfate | 48 | $1,086 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 23 | $950 |
| Cyclobenzaprine Hcl | 85 | $882 |
| Levofloxacin | 136 | $581 |
| Methocarbamol | 37 | $571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $165 | $14,60813 claims |
| Redhill Biopharma Inc.Movantik | $25 | $13,09525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 interventional pain medicine providers in Michigan.
Other interventional pain medicine in Lansing
- Narasimha GundamrajLansing$5K
- Kevin OrrLansing$2K
- Malani GuptaLansing$2K
- Jane SolomonsLansing$1K
- Subhash GuptaLansing$959
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.